Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors

Summary

To establish the maximum tolerated dose (MTD) of INCB007839 given as multiple doses for 28 days and to determine if a higher MTD can be established when INCB007839 is administered in combination with prophylactic anticoagulation and with a 2 and a half day (5 doses) treatment interruption every two weeks.

Timeline

Start

2005-01

Primary completion

2009-01

Completion

2009-01

Drugs

Indications